‹ AMRX latest research

AMRX (Amneal Pharmaceuticals, Inc.): every AI call and what happened next

TradeFlare's AI research teams analysed AMRX on 13 market nights between May 11, 2026 and September 25, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.

13 calls 6 BUY · 6 HOLD · 1 SELL BUY calls up after 20 trading days: 3 of 6
DateVerdictPriceTarget / stop5 days later20 days laterWhy (that night)
September 25, 2026 HOLD $19.81 — / — +2.7% not yet
The stock is exhibiting post-earnings drift but faces significant fundamental headwinds and high risk.
September 24, 2026 HOLD $19.33 — / — +1.3% not yet
The current setup does not warrant a BUY, and the market regime is neutral, suggesting caution.
September 23, 2026 HOLD $19.50 $23.40 / $16.58 +4.2% not yet
The post-earnings drift is a short-to-medium term catalyst.
September 22, 2026 HOLD $20.16 $23.18 / $17.14 +3.6% not yet
The post-earnings drift suggests a short-to-medium term upward trend, but the high risk profile warrants a cautious approach.
September 21, 2026 HOLD $18.71 $22.45 / $15.90 +1.7% not yet
The PEAD signal suggests short-term momentum, but the overall risk profile and mixed team signals warrant a cautious approach.
August 14, 2026 BUY $17.27 — / — -1.3% -5.1%
The stock is currently in a neutral market regime and the technicals are mixed, making it unsuitable for a new buy.
August 13, 2026 BUY $17.66 — / — +3.6% -1.5%
The scanner triggered on an RSI pullback, suggesting potential for a short-term bounce.
August 12, 2026 HOLD $17.10 — / — +2.5% -4.5%
Positive sentiment driven by strong Q2 earnings and raised outlook.
August 6, 2026 BUY $18.46 — / — -4.4% -1.1%
Strong Q2 earnings beat and raised guidance driving positive sentiment.
May 14, 2026 BUY $12.39 $13.50 / $10.53 +1.6% +32.5%
The current market regime and the stock's technicals do not support a buy decision.
May 13, 2026 BUY $12.60 — / — -1.3% +31.9%
The current market regime and the stock's fundamental weakness necessitate a cautious approach, waiting for a clearer catalyst or improved risk profile.
May 12, 2026 SELL $12.78 — / — -6.3% +21.6%
Continued positive sentiment from strong Q1 earnings.
May 11, 2026 BUY $13.20 $14.66 / $11.22 -6.7% +14.9%
The stock is consolidating near resistance with mixed technical signals and high risk factors, requiring a clearer catalyst or technical setup.

Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.